Needham keeps USD 35.00 target for ACADIA Pharmaceuticals stock
Published on 10/20/2026 at 18:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and earnings
- Needham maintained its USD 35.00 target and Buy rating for ACADIA Pharmaceuticals on October 19, 2026.
- Second-quarter revenue reached USD 308.00 million, up 16.40 percent year over year.
- ACADIA Pharmaceuticals stock costs EUR 18.07 at Lang & Schwarz on October 20, 2026 at 6:31 p.m. CEST.
- ACADIA Pharmaceuticals is scheduled to report third-quarter results on November 4, 2026.
Needham maintained a USD 35.00 price target and Buy rating for ACADIA Pharmaceuticals on October 19, 2026, according to GuruFocus. The target is 72.75 percent above the USD 20.26 Nasdaq price quoted on October 20, 2026. ACADIA stock stood at EUR 18.07 at Lang & Schwarz on October 20, 2026 at 6:31 p.m. CEST.
Revenue growth supports the setup
ACADIA reported USD 308.00 million in revenue for the second quarter of 2026, a 16.40 percent increase from the same quarter a year earlier. MarketBeat reported that quarterly earnings per share reached USD 0.18, exceeding the USD 0.07 consensus estimate by USD 0.11. The result gives the upcoming report a clear numerical benchmark.
Price remains near the yearly low
ACADIA's USD 18.39 to USD 30.96 52-week range places the Nasdaq price of USD 20.26 only 10.17 percent above the low and 34.56 percent below the high. The company's market capitalization was USD 3.5 billion on October 20, 2026, while its price-to-earnings ratio was 9.14. Those figures put the stock well below its recent high despite the reported revenue increase.
What comes before the next report?
ACADIA is scheduled to report third-quarter 2026 results on November 4, 2026, after the market closes, with a conference call planned for 4:30 p.m. ET, according to MarketBeat. The same estimate calls for revenue of USD 332.47 million and earnings per share of USD 0.1992. That would represent a 7.95 percent increase over second-quarter revenue, although the estimate remains below the USD 0.42 earnings per share reported for the same quarter a year earlier.
Business remains centered on neurology
ACADIA develops and commercializes therapies for central nervous system disorders and rare diseases. Its marketed medicines include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, while its pipeline extends into Alzheimer's disease psychosis and Lewy body dementia psychosis.
Stock price and investor view
The combination of a USD 35.00 Needham target, second-quarter revenue of USD 308.00 million and a November 4 reporting date gives investors three dated reference points for the next phase. The euro quotation stood at EUR 18.07 at Lang & Schwarz on October 20, 2026 at 6:31 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of ACADIA Pharmaceuticals stock.
ACADIA Pharmaceuticals stock at a glance
- Company: Acadia Pharmaceuticals Inc.
- ISIN: US0042251084
- Ticker: ACAD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 6:31 p.m. CEST): EUR 18.07
- Market capitalization: USD 3.5 billion (as of October 20, 2026)
- 52-week range: USD 18.39-30.96 (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 4, 2026
Market context: Market report Nasdaq Composite.
